"Share your clinical breakthroughs with the world. Submit your research to the International Journal of Clinical and Medical Case Studies today."
Submit Manuscript Contact UsInternational Journal of Clinical and Medical Case Studies is a peer-reviewed, open-access journal that focuses on the publication of insightful, real-world case studies that contribute to the advancement of medical science and clinical practice. By highlighting unique and rare clinical cases, the journal provides healthcare professionals and researchers with the opportunity to share critical observations and medical breakthroughs, fostering a deeper understanding of complex conditions.
Read MoreIn patients with severe OAT, sperm selection for Intracytoplasmic Sperm Injection (ICSI) poses a significant challenge due to extremely low sperm count, poor motility, and high levels of morphological abnormalities.
The increased cellular permeability syndrome related to relative dopamine deficiency allowing infiltration of unwanted irritants into various tissues may be the most common cause of a great number of chronic disorders including pain or organ dysfunction.
The ameloblastoma, first reported as an "odontome" in 1827, has long been known as one of the most unusual and complex of odontogenic tumors, with a variety of clinical and microscopic types (Table 1) [1,2]. By 1928 it became clear that this benign, locally aggressive neoplasm with its large growth potential had an additional unique feature.
In contrast to alopecia related to conversion of terminal hairs to vellus hairs on a genetic/hormonal basis, Alopecia Areata (AA) is considered to have an inflammatory basis with psychogenetic and possible genetic contribution. Thus, most treatments that have been tried for AA have been attempts to interrupt the inflammatory pathways.
Non-Small Cell Lung Cancer (NSCLC) frequently harbors actionable genetic alterations, including RET fusions, which occur in 1–2% of cases, predominantly in adenocarcinomas. Selpercatinib, a selective RET inhibitor, has significantly improved outcomes in these patients, demonstrating high response rates even following prior therapies.